These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35764249)

  • 1. Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-α2a.
    Hauptstein N; Pouyan P; Wittwer K; Cinar G; Scherf-Clavel O; Raschig M; Licha K; Lühmann T; Nischang I; Schubert US; Pfaller CK; Haag R; Meinel L
    J Control Release; 2022 Aug; 348():881-892. PubMed ID: 35764249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Insights into Site-Specific Interferon-α2a Bioconjugates Originated from PEG, LPG, and PEtOx.
    Hauptstein N; Pouyan P; Kehrein J; Dirauf M; Driessen MD; Raschig M; Licha K; Gottschaldt M; Schubert US; Haag R; Meinel L; Sotriffer C; Lühmann T
    Biomacromolecules; 2021 Nov; 22(11):4521-4534. PubMed ID: 34643378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linear Polyglycerol for N-terminal-selective Modification of Interleukin-4.
    Tully M; Hauptstein N; Licha K; Meinel L; Lühmann T; Haag R
    J Pharm Sci; 2022 Jun; 111(6):1642-1651. PubMed ID: 34728175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zwitterlation mitigates protein bioactivity loss
    Han Y; Yuan Z; Zhang P; Jiang S
    Chem Sci; 2018 Dec; 9(45):8561-8566. PubMed ID: 30568780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase].
    Hui X; Cao W; Zhang D; Ge W; Li S; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):750-762. PubMed ID: 32347069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation.
    Lewis A; Tang Y; Brocchini S; Choi JW; Godwin A
    Bioconjug Chem; 2008 Nov; 19(11):2144-55. PubMed ID: 18973286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.
    Tully M; Wedepohl S; Kutifa D; Weise C; Licha K; Schirner M; Haag R
    Eur J Pharm Biopharm; 2021 Jul; 164():105-113. PubMed ID: 33957224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.
    Barril G; Quiroga JA; Sanz P; Rodrìguez-Salvanés F; Selgas R; Carreño V
    Aliment Pharmacol Ther; 2004 Jul; 20(1):37-44. PubMed ID: 15225169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.
    Podobnik B; Helk B; Smilović V; Škrajnar Š; Fidler K; Jevševar S; Godwin A; Williams P
    Bioconjug Chem; 2015 Mar; 26(3):452-9. PubMed ID: 25629733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One to one comparison of cell-free synthesized erythropoietin conjugates modified with linear polyglycerol and polyethylene glycol.
    Pouyan P; Zemella A; Schloßhauer JL; Walter RM; Haag R; Kubick S
    Sci Rep; 2023 Apr; 13(1):6394. PubMed ID: 37076514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients.
    Espinosa M; Arenas MD; Aumente MD; Barril G; Buades JM; Aviles B; Carretero D; Alvarez-Lara MA; Carnicer F; Martin-Malo A; Aljama P
    Clin Nephrol; 2007 Jun; 67(6):366-73. PubMed ID: 17598372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers.
    Dhalluin C; Ross A; Leuthold LA; Foser S; Gsell B; Müller F; Senn H
    Bioconjug Chem; 2005; 16(3):504-17. PubMed ID: 15898716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.
    Hadziyannis SJ; Papatheodoridis GV
    Expert Opin Pharmacother; 2003 Apr; 4(4):541-51. PubMed ID: 12667117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyglycerol for Half-Life Extension of Proteins-Alternative to PEGylation?
    Tully M; Dimde M; Weise C; Pouyan P; Licha K; Schirner M; Haag R
    Biomacromolecules; 2021 Apr; 22(4):1406-1416. PubMed ID: 33792290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy.
    Hu J; Wang G; Zhao W; Gao W
    J Control Release; 2016 Sep; 237():71-7. PubMed ID: 27393654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2.
    Dhalluin C; Ross A; Huber W; Gerber P; Brugger D; Gsell B; Senn H
    Bioconjug Chem; 2005; 16(3):518-27. PubMed ID: 15898717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
    Foster GR
    Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.